Extended Data Fig. 6: Drug candidates promotes the expression of genes in the antigen presentation of breast tumour cells. | Nature Biomedical Engineering

Extended Data Fig. 6: Drug candidates promotes the expression of genes in the antigen presentation of breast tumour cells.

From: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Extended Data Fig. 6: Drug candidates promotes the expression of genes in the antigen presentation of breast tumour cells.

a, Gene-set enrichment plot of the antigen processing and presentation pathway in EO771 cells treated with BML-210 in comparison with the cells treated with vehicle control. b, Validation of up-regulated genes from Fig. 6c in human MDA-MB-468 cells treated with vehicle control or BML-210 (1.0 μM) by quantitative RT-PCR. c, Levels of HLA-A,B,C on the NY-ESO-1+ MDA-MB-468 cells treated with control or BML-201, determined by MFI in flow cytometry analysis. d, H-2k expression levels in the OVA+ EO771 cells treated with CUDC-101 or GSK-LSD1 were determined by qRT-PCR. e, HLA gene expression levels in NY-ESO-1+ MDA-MB-468 cells treated with CUDC-101 or GSK-LSD1 were determined by qRT-PCR. f, B2M expression levels in the OVA+ EO771 cells treated with CUDC-101 or GSK-LSD1 were determined by qRT-PCR. g,h, The effect of drug treatment on the H-2Kb and HLA-A2 antigen presentation on OVA+ EO771 cells and NY-ESO-1+ MDA-MB-468 cells, respectively. Data (b,d-f) from 3 biologically parallel experiments were analyzed using Two-way ANOVA. Data (c,g,h) from 3 biologically parallel experiments were analyzed using One-way ANOVA. ***, p < 0.001; ****, p < 0.0001; ns, no significance.

Back to article page